DDW Highlights: 26 March 2026

The University of Edinburgh’s synthetic‑biology team has re‑engineered E. coli to convert post‑consumer PET bottles into L‑DOPA, the cornerstone treatment for Parkinson’s disease. By depolymerising 50 million tonnes of annual PET waste into p‑terephthalic acid and then biologically reshaping it into the drug, researchers demonstrate a scalable route that merges waste remediation with pharmaceutical manufacturing. This bio‑upcycling model not only reduces plastic pollution but also creates a new feedstock pipeline for high‑value chemicals, positioning the sector for greener, circular production.

In parallel, a functional‑genomic screen uncovered DHX8 as a pivotal regulator of the HSF1 stress‑response pathway in cancer cells. Disruption of DHX8 collapses the protective network that tumors exploit to survive oncogenic stress, leading to growth arrest or cell death across multiple cancer types. The discovery highlights an unexpected RNA‑processing vulnerability and sets the stage for small‑molecule probes that could translate into novel anticancer therapeutics. By targeting a core stress‑adaptation mechanism, future drugs may achieve broader efficacy with reduced resistance.

Multiple myeloma research also advanced with the validation of kappa (KMA) and lambda (LMA) myeloma antigens as highly specific markers absent from normal plasma cells. These antigens enable next‑generation antibody and CAR‑T strategies, exemplified by capamab’s phase 2b success when combined with Revlimid and dexamethasone, and a KMA‑targeted CAR‑T now entering phase 1 trials. Precision targeting promises to spare healthy immune cells while delivering potent anti‑myeloma activity, potentially reshaping treatment algorithms for relapsed‑refractory disease. Together, these breakthroughs illustrate a rapid shift toward sustainable drug synthesis, genomics‑driven oncology, and highly selective immunotherapies.